Vitiligo

TEL AVIV, Israel, September 2, 2026 Teva Pharmaceutical Industries Ltd. has reported positive topline results from its ongoing Phase...

Amsterdam, the Netherlands – August 27, 2026 argenx announced the successful completion of its acquisition of Forte Biosciences, Inc.,...

NEW YORK, July 30, 2026 Pfizer Inc. announced positive topline Phase 3 results for LITFULO™ (ritlecitinib) in patients with...

North Chicago, Ill., July 29, 2026 AbbVie announced that the European Commission (EC) has approved RINVOQ® (upadacitinib) for the...

Beijing, July 16, 2026 InnoCare Pharma announced that the Phase II portion of its adaptive Phase II/III clinical trial...

MELBOURNE, Australia & AMSTERDAM, Netherlands, April 24, 2026 Clinuvel Pharmaceuticals Ltd has announced that it has received final Scientific...